Sukus, there’s actually a lot of data that should be forthcoming after TLD on DCVaxL that’s outside this phase III. Besides the clinical trial I mentioned for patients that failed to get in the main trial, we have the 32 patients placed in the pseudoprogressor arm, and the 55-patient information arm. The info arm we have data on.
We also have the Phase I and Phase II trial for DCVaxL with ICLC and another antibody. I think both trial info has been released, though they never revealed how the DCVaxL arm did, understandably. The data for DCVaxL +ICLC was GREAT.
We also have numerous companionate care patients and self-pay patients ....I don’t know if they are the same group. I believe some of them were combined with Checkpoint inhibitors, which is why experts in the field believe our vaccine and CIs may have synergy.
We also know from Linda’s comments that DCVaxL was given to other cancer patients in Israel and showed similar efficacy. I believe she specifically mentioned a few of them, including colorectal cancer.
And we know from the ovarian cancer trial in PA that it has been shown in a Phase I trial to work in that cancer. Question: if this trial is approved, will it quickly be approved in ovarian cancer?
In addition, how well will DCVaxL work when it is given immediately after leukopherisis, an 8 day process to create the vaccine, rather than waiting the 3 months to go through chemorad, which might or might not still be given, and randomization that is required in a clinical trial?
How much better will the vaccine work once it is automated? ...a process we believe will also enrich the immature DCs?
How much better will it work with German optimization? Whatever that is? A question of great interest here on the board.
And of course, let’s remember that GBM is not only the mother of all brain cancers, but also the mother of all cancers. Not only do we have to defeat cancer, but we also had to get across the blood/brain barrier!
If we show 20% cure (5 years or more OS) in GBM, then what kind of efficacy/cure will we see in the less deadly and slower killing cancers? Lung, bladder, colon, ovarian, to name a few?
And did I almost forget to mention that DCVaxL works best in the meschemyl (sp) gene type. The toughest gene of all to detest and that’s the gene type that travels through the blood and creates metastases, in other words, the real killer for most cancers.
I would say I’m dying to find out these answers, but with two sisters surviving cancers and a third, a benign brain tumor, I’ll just say I can wait. But hurry up, NWBO!
AI
